Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (Nasdaq: CRDF) has appointed Dr. Fairooz Kabbinavar as its new chief medical officer, effective January 30, 2023. With over 30 years of experience in oncology, Dr. Kabbinavar will lead the clinical development of onvansertib, a promising treatment for colorectal cancer and other solid tumors. His prior roles include significant contributions to the approval of bevacizumab for metastatic colorectal cancer. His expertise aims to streamline Cardiff's clinical programs, particularly those targeting KRAS-mutated metastatic colorectal cancer. The Board has granted him 425,000 stock options at an exercise price of $1.75 per share.
Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The chat will take place on January 18 at 1:30 PM ET. Investors can register for the live webcast through the provided link. Cardiff Oncology is focused on developing therapies leveraging PLK1 inhibition to treat various cancers, including KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. For more details, visit their official website.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 3:55 PM GMT (10:55 AM ET) and will include a corporate presentation followed by a Q&A session. The company focuses on PLK1 inhibition in developing therapies for cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. A replay will be available on their website for 90 days.
Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 trial results for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC), showing durable responses and positioning for a Phase 2 trial, ONSEMBLE, set to start in Q4 2022. As of September 30, 2022, the company has approximately $114 million in cash, projected to fund operations into 2025. The objective response rate for patients was 35%, significantly exceeding historical controls, with better outcomes in bevacizumab-naïve patients (ORR 69%).
Cardiff Oncology (CRDF) announced plans for a randomized Phase 2 trial, ONSEMBLE, to evaluate onvansertib's efficacy in second-line RAS-mutated metastatic colorectal cancer (mCRC), with topline data expected in 2H 2024. The ongoing Phase 1b/2 trial shows a median duration of response of 11.7 months. Initial results in a Phase 2 trial for pancreatic cancer indicate promising responses. The company's cash resources are projected to cover operations into 2025, emphasizing a strategic focus on mCRC and pancreatic cancer while discontinuing prostate cancer activities.
Cardiff Oncology (Nasdaq: CRDF) announced promising results from its Phase 1b/2 clinical trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a median duration of response (mDoR) of 11.7 months and an overall response rate (ORR) of 35%, surpassing historical benchmarks. Additionally, patients with a ≥90% decrease in KRAS mutant allele frequency showed significantly better outcomes. These findings suggest onvansertib may address critical treatment gaps in mCRC, with further data presented at ESMO Congress 2022.
Cardiff Oncology, Inc. (Nasdaq: CRDF) will participate in the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY. The Baird Conference is on September 13, 2022, featuring a fireside chat at 2:00 PM ET. The H.C. Wainwright Conference is on September 14, 2022, with a corporate presentation at the same time. The company focuses on developing novel therapies for various cancers, leveraging PLK1 inhibition through their lead asset, onvansertib. More details are available on their official website.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, scheduled for September 9-13 in Paris. The presentations focus on the efficacy of onvansertib, a PLK1 inhibitor, in overcoming irinotecan resistance in KRAS-mutated metastatic colorectal cancer. The data suggest early decreases in KRAS mutant allele frequency (MAF) may predict patient response. A conference call on September 12 will discuss clinical updates and development pathways for onvansertib.
Cardiff Oncology, Inc. (Nasdaq: CRDF) will host a webcast and conference call on September 12, 2022, at 4:30 PM ET, to discuss the development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer, alongside updates on other programs. The event will include ongoing clinical trial data updates. In addition, Cardiff management will attend the Baird Global Healthcare Conference on September 13 and the H.C. Wainwright Global Investment Conference on September 14. Details of the call can be found on their website.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced significant progress in cancer therapies, presenting promising preclinical data at AACR. Notably, onvansertib combined with olaparib showed a statistically significant survival benefit in ovarian cancer models. In metastatic castration-resistant prostate cancer (mCRPC), updated clinical results indicated increasing disease control rates with higher onvansertib doses, reaching 75% in the most intense treatment group. As of June 30, 2022, the company reported $122 million in cash, with an increase in operating expenses driven by R&D efforts and staff expansion.